Top

Published in:

01-06-2015 | Decompensated Heart Failure (JE Ho, Section Editor)

Venous Congestion, Endothelial and Neurohormonal Activation in Acute Decompensated Heart Failure: Cause or Effect?

Authors: Paolo C. Colombo, Amanda C. Doran, Duygu Onat, Ka Yuk Wong, Myra Ahmad, Hani N. Sabbah, Ryan T. Demmer

Published in: Current Heart Failure Reports | Issue 3/2015

Abstract

Venous congestion and endothelial and neurohormonal activation are known to occur in acute decompensated heart failure (ADHF), yet the temporal role of these processes in the pathophysiology of decompensation is not fully understood. Conventional wisdom presumes congestion to be a consequence of worsening cardiovascular function; however, the biomechanically driven effects of venous congestion are biologically plausible contributors to ADHF that remain largely unexplored in vivo. Recent experimental evidence from human models suggests that fluid accumulation and venous congestion are not simply consequences of poor cardiovascular function, but rather are fundamental pro-oxidant, pro-inflammatory, and hemodynamic stimuli that contribute to acute decompensation. The latest advances in the monitoring of volume status using implantable devices allow for the detection of venous congestion before symptoms arise. This may ultimately lead to improved treatment strategies including not only diuretics, but also specific, adjuvant interventions to counteract endothelial and neurohormonal activation during early preclinical decompensation.

Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). J Card Fail. 2008;14(9):777–84. doi:10.1016/j.cardfail.2008.07.188.CrossRefPubMedCentralPubMed

Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582–8. doi:10.1016/j.jacc.2008.08.080.CrossRefPubMed

Felker GM, Adams Jr KF, Konstam MA, O’Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145(2 Suppl):S18–25. doi:10.1067/mhj.2003.150.CrossRefPubMed

Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167(14):1493–502. doi:10.1001/archinte.167.14.1493.CrossRefPubMed

Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153(6):1021–8. doi:10.1016/j.ahj.2007.03.012.CrossRefPubMed

Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119(12 Suppl 1):S3–10. doi:10.1016/j.amjmed.2006.09.011.CrossRefPubMed

Gheorghiade M, Gattis WA, O’Connor CM, Adams Jr KF, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963–71. doi:10.1001/jama.291.16.1963.CrossRefPubMed

Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958–68. doi:10.1161/CIRCULATIONAHA.105.590091.CrossRefPubMed

Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140(6):840–7. doi:10.1067/mhj.2000.110933.CrossRefPubMed

10.

Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure—re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10(2):165–9. doi:10.1016/j.ejheart.2008.01.007.CrossRefPubMed

11.

Dorhout Mees EJ. Diastolic heart failure: a confusing concept. Heart Fail Rev. 2013;18(4):503–9. doi:10.1007/s10741-012-9344-9.CrossRefPubMed

12.

Felker GM, Cotter G. Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. Am Heart J. 2006;151(4):765–7. doi:10.1016/j.ahj.2005.07.004.CrossRefPubMed

13.

Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112(6):841–8. doi:10.1161/CIRCULATIONAHA.104.492207.CrossRefPubMed

14.

Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Maeda K, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 1995;76(11):803–8.CrossRefPubMed

15.

Andreassen AK, Nordoy I, Simonsen S, Ueland T, Muller F, Froland SS, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 1998;81(5):604–8.CrossRefPubMed

16.

Klein RM, Breuer R, Mundhenke M, Schwartzkopff B, Strauer BE. Circulating adhesion molecules (cICAM-1, lcVCAM-1) in patients with suspected inflammatory heart muscle disease. Z Kardiol. 1998;87(2):84–93.CrossRefPubMed

17.

Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 2003;5(4):507–16.CrossRefPubMed

18.

Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998;79(4):399–407.CrossRefPubMed

19.

Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;77(9):723–7.CrossRefPubMed

20.

Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964–71.CrossRefPubMed

21.

Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 1995;92(6):1379–82.CrossRefPubMed

22.

Carlstedt F, Lind L, Lindahl B. Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med. 1997;242(5):361–5.CrossRefPubMed

23.

Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Sakoda T, Ohyanagi M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine. 2010;49(3):264–8. doi:10.1016/j.cyto.2009.11.006.CrossRefPubMed

24.

Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77(6):550–6. doi:10.1038/ki.2009.503.CrossRefPubMed

25.

Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995;154(2):882–92.PubMed

26.

Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30(2):215–23. doi:10.1006/jmcc.1997.0592.CrossRefPubMed

27.

Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology. 2001;96(3–4):144–54.CrossRefPubMed

28.

Rodeheffer RJ, Lerman A, Heublein DM, Burnett Jr JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992;67(8):719–24.CrossRefPubMed

29.

Cottone S, Mule G, Guarneri M, Palermo A, Lorito MC, Riccobene R, et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant. 2009;24(2):497–503. doi:10.1093/ndt/gfn489.CrossRefPubMed

30.

Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63(3):645–51.CrossRefPubMed

31.

Lauten A, Ferrari M, Goebel B, Rademacher W, Schumm J, Uth O, et al. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Eur J Heart Fail. 2011;13(7):711–7. doi:10.1093/eurjhf/hfr043.CrossRefPubMed

32.

Paton AM, Lever AF, Oliver NW, Medina A, Briggs JD, Morton JJ, et al. Plasma angiotensin II, renin, renin-substrate and aldosterone concentrations in acute renal failure in man. Clin Nephrol. 1975;3(1):18–23.PubMed

33.

Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724–9.CrossRefPubMed

34.

Milo O, Cotter G, Kaluski E, Brill A, Blatt A, Krakover R, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92(2):222–6.CrossRefPubMed

35.

White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin MC, et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond). 2006;110(4):483–9. doi:10.1042/CS20050317.CrossRef

36.

Gutierrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernandez-Aviles F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34(41):3175–81. doi:10.1093/eurheartj/eht351.CrossRefPubMedCentralPubMed

37.

Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60(16):1455–69. doi:10.1016/j.jacc.2011.11.082.CrossRefPubMed

38.

Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69. doi:10.7150/ijbs.7502.CrossRefPubMedCentralPubMed

39.

Zhou J, Li YS, Chien S. Shear stress-initiated signaling and its regulation of endothelial function. Arterioscler Thromb Vasc Biol. 2014;34(10):2191–8. doi:10.1161/ATVBAHA.114.303422.CrossRefPubMed

40.

Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol. 2008;93(1):141–7. doi:10.1113/expphysiol.2007.038588.CrossRefPubMed

41.

Cannon 3rd RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44(8 Pt 2):1809–19.PubMed

42.

Drexler H. Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation. 1999;99(23):2972–5.CrossRefPubMed

43.

Starling RC. Inducible nitric oxide synthase in severe human heart failure: impact of mechanical unloading. J Am Coll Cardiol. 2005;45(9):1425–7. doi:10.1016/j.jacc.2005.02.021.CrossRefPubMed

44.

Boo YC. Shear stress stimulates phosphorylation of protein kinase A substrate proteins including endothelial nitric oxide synthase in endothelial cells. Exp Mol Med. 2006;38(4):453. doi:10.1038/emm.2006.53.CrossRefPubMed

45.

Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. 2003;93(4):354–63. doi:10.1161/01.RES.0000089257.94002.96.CrossRefPubMed

46.

Hsieh HJ, Liu CA, Huang B, Tseng AH, Wang DL. Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. J Biomed Sci. 2014;21:3. doi:10.1186/1423-0127-21-3.CrossRefPubMedCentralPubMed

47.

Hasdai D, Holmes Jr DR, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation. 1997;95(2):357–62.CrossRefPubMed

48.

Delli Gatti C, Osto E, Kouroedov A, Eto M, Shaw S, Volpe M, et al. Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. Clin Exp Hypertens. 2008;30(7):616–27. doi:10.1080/10641960802443183.CrossRefPubMed

49.

Cheng JJ, Wung BS, Chao YJ, Wang DL. Cyclic strain enhances adhesion of monocytes to endothelial cells by increasing intercellular adhesion molecule-1 expression. Hypertension. 1996;28(3):386–91.CrossRefPubMed

50.

Kawai M, Naruse K, Komatsu S, Kobayashi S, Nagino M, Nimura Y, et al. Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: clinical and experimental studies. J Hepatol. 2002;37(2):240–6.CrossRefPubMed

51.

Wang BW, Chang H, Lin S, Kuan P, Shyu KG. Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc Res. 2003;59(2):460–9.CrossRefPubMed

52.

Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med. 2009;6(1):16–26. doi:10.1038/ncpcardio1397.CrossRefPubMedCentralPubMed

53.

Canty Jr TG, Boyle Jr EM, Farr A, Morgan EN, Verrier ED, Pohlman TH. Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha. Circulation. 1999;100(19 Suppl):II361–4.PubMed

54.

Boyle Jr EM, Canty Jr TG, Morgan EN, Yun W, Pohlman TH, Verrier ED. Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription. Ann Thorac Surg. 1999;68(5):1949–53.CrossRefPubMed

55.

Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol. 2004;164(3):1049–61.CrossRefPubMedCentralPubMed

56.

Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95(8):773–9. doi:10.1161/01.RES.0000145728.22878.45.CrossRefPubMed

57.

Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002;34(12):1508–12.CrossRefPubMed

58.

Onat D, Jelic S, Schmidt AM, Pile-Spellman J, Homma S, Padeletti M, et al. Vascular endothelial sampling and analysis of gene transcripts: a new quantitative approach to monitor vascular inflammation. J Appl Physiol. 2007;103(5):1873–8. doi:10.1152/japplphysiol.00367.2007.CrossRefPubMed

59.

Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005;111(1):58–62. doi:10.1161/01.CIR.0000151611.89232.3B.CrossRefPubMed

60.

Colombo PC, Rastogi S, Onat D, Zaca V, Gupta RC, Jorde UP, et al. Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail. 2009;15(5):457–63. doi:10.1016/j.cardfail.2008.12.006.CrossRefPubMed

61.••

Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2014;35(7):448–54. doi:10.1093/eurheartj/eht456. This recent article provides mechanistic in vivo evidence for a link between peripheral venous congestion and activation of the inflammatory/oxidative program within endothelial cells of humans.CrossRefPubMedCentralPubMed

62.

Colombo PC, Onat D, Harxhi A, Hayashi Y, Wong KY, Uriel N, et al. Acute venous congestion enhances vasoconstriction, inflammation, endothelial activation and oxidative stress in compensated ambulatory patients with systolic heart failure on an optimized medical regimen. Circulation (AHA abstract). 2014.

63.

Hawk C, Hayashu Y, Kin J, Chudasama N, Ramnauth DS, Wong KY, et al. Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans. Circulation (AHA abstract). 2014.

64.••

Cui J, McQuillan P, Moradkhan R, Pagana C, Sinoway LI. Sympathetic responses during saline infusion into the veins of an occluded limb. J Physiol. 2009;587(Pt 14):3619–28. doi:10.1113/jphysiol.2009.173237. This important article demonstrates that peripheral venous congestion is sufficient to evoke systemic sympathetic activation.CrossRefPubMedCentralPubMed

65.

Cui J, McQuillan PM, Blaha C, Kunselman AR, Sinoway LI. Limb venous distension evokes sympathetic activation via stimulation of the limb afferents in humans. Am J Physiol Heart Circ Physiol. 2012;303(4):H457–63. doi:10.1152/ajpheart.00236.2012.CrossRefPubMedCentralPubMed

66.

Cui J, Leuenberger UA, Gao Z, Sinoway LI. Sympathetic and cardiovascular responses to venous distension in an occluded limb. Am J Physiol Regul Integr Comp Physiol. 2011;301(6):R1831–7. doi:10.1152/ajpregu.00170.2011.CrossRefPubMedCentralPubMed

67.••

Cui J, Gao Z, Blaha C, Herr MD, Mast J, Sinoway LI. Distension of central great vein decreases sympathetic outflow in humans. Am J Physiol Heart Circ Physiol. 2013;305(3):H378–85. doi:10.1152/ajpheart.00019.2013. This important study demonstrated that central saline infusion leads to activation of the sympathetic response, increase in blood pressure and decrease in MSNA levels. CrossRefPubMedCentralPubMed

68.

Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100(9):999–1008.CrossRefPubMed

69.

Masoumi A, Ortiz F, Radhakrishnan J, Schrier RW, Colombo PC. Mineralocorticoid receptor antagonists as diuretics: can congestive heart failure learn from liver failure? Heart Fail Rev. 2014. doi:10.1007/s10741-014-9467-2.

70.

Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112(14):2193–200. doi:10.1161/CIRCULATIONAHA.105.535435.CrossRefPubMed

71.

Chen X, Rahman MA, Floras JS. Effects of forearm venous occlusion on peroneal muscle sympathetic nerve activity in healthy subjects. Am J Cardiol. 1995;76(3):212–4.CrossRefPubMed

72.

Colombo PC, Onat D, Sabbah HN. Acute heart failure as “acute endothelitis”—interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail. 2008;10(2):170–5. doi:10.1016/j.ejheart.2007.12.007.CrossRefPubMed

73.•

Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–66. doi:10.1016/S0140-6736(11)60101-3. This landmark study introduces the advantages of long term invasive hemodynamic monitoring in heart failure.CrossRefPubMed

74.•

Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44. doi:10.1161/CIRCHEARTFAILURE.113.001229. This recent article demonstrates the successful use of invasive hemodynamic monitoring for the long term management of heart failure in order to prevent heart failure hospitalizations.CrossRefPubMed

Title: Venous Congestion, Endothelial and Neurohormonal Activation in Acute Decompensated Heart Failure: Cause or Effect?
Authors: Paolo C. Colombo
Amanda C. Doran
Duygu Onat
Ka Yuk Wong
Myra Ahmad
Hani N. Sabbah
Ryan T. Demmer
Publication date: 01-06-2015
Publisher: Springer US
Published in: Current Heart Failure Reports / Issue 3/2015
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-015-0254-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Cellular Immunity and Cardiac Remodeling After Myocardial Infarction: Role of Neutrophils, Monocytes, and Macrophages

Utilizing Cardiac Biomarkers to Detect and Prevent Chemotherapy-Induced Cardiomyopathy

Tailoring of Self-Management Interventions in Patients With Heart Failure

Sarcopenic Obesity and the Pathogenesis of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction

Patient-Reported Outcomes in Heart Failure: Existing Measures and Future Uses

Is There a Role for Invasive Hemodynamic Monitoring in Acute Heart Failure Management?

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage